GLP-1’s for Men: Weight Loss with Benefits
Few drug classes have moved this fast from diabetes clinics to dinner-table conversation. Semaglutide (Ozempic, Wegovy), Tirzepatide (Mounjaro, Zepbound), and their relatives — collectively known as GLP-1 receptor agonists — were originally built to manage blood sugar in type 2 diabetes. Today they're reshaping how men think about weight, metabolic health, and even hormone levels (news.llu.edu). They are also some of the most successful medications in history (selling between 60 to 110 Billion dollars worth in 2025 alone This is between Novo Nordisc and Eli Lilly which claims 90% of the market. An recent estimate claims that approximately 1 in 8 people in the USA are using one of them and as per a 2026 Leger survey approximately 3 million Canadians have used one of them in the past 12 months. Usage of GLP-1’s has quadrupled in both countries over the past three years. This will continue to accelerate as the prices come down acceptance goes up and with generic versions launching onto the market and with the introduction of GLP-1’s in pill form.
Like any powerful medication, GLP-1s come with trade-offs. Here's a clear-eyed look at what the evidence shows — the upside, the downside, and what a man considering one of these drugs should ask his doctor.
How GLP-1 Medications Work
They were first developed for Type 2 diabetes but were then found to be excellent at treating obesity. They have now been approved for a number of other medical conditions including but not limited to cardiovascular disease, sleep apnea, chronic kidney disease and metabolic liver disease. GLP-1 receptor agonists mimic a natural gut hormone that slows digestion, boosts insulin release, and signals the brain that you're full. That combination helps reduce appetite and food intake, which is why the drugs produce such substantial weight loss compared with older obesity medications (StatPearls/NCBI, PMC).
Semaglutide has produced average weight loss of around 15% of body weight in major trials, while the dual GLP-1/GIP agonist tirzepatide has pushed that closer to 20–22% over 72–88 weeks (PMC, Men's Health). Men, on average, tend to lose a somewhat smaller percentage of body weight than women on the same dose, though the absolute health gains are still significant (TrimRx). They are particularly helpful for people who eat healthy, exercise regularly yet seem stuck at a body weight both they and their doctor knows is not healthy longterm.
The Benefits: More Than Just Weight Loss
Cardiovascular protection. This is arguably the most important finding of the last few years. The SELECT trial showed semaglutide reduced major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) by about 20% in people with existing heart disease and obesity, even without diabetes (PMC). A broader meta-analysis found GLP-1 receptor agonists lowered all-cause mortality, cardiovascular death, and major cardiac events across multiple trials (PubMed, JAMA Network).
Blood sugar and metabolic health. Beyond the original diabetes indication, GLP-1s meaningfully improve insulin sensitivity, blood pressure, and cholesterol, and have been shown to reduce liver fat and inflammation in patients with fatty liver disease (PMC).
Kidney and Sleep Apnea benefits. Large trials have linked GLP-1 use to reduced rates of chronic kidney disease progression, and tirzepatide has shown reductions in sleep apnea severity as high as 48–56% compared with placebo (PMC, PMC).
Testosterone and sexual function — a nuancwin for men. This is where things get particularly relevant for men's health. Obesity itself suppresses testosterone, and multiple studies show that GLP-1-driven weight loss helps restore it. A 2025 study presented at the Endocrine Society found men treated with GLP-1 therapies — semaglutide, dulaglutide, and tirzepatide — experienced significant increases in both total and free testosterone (Healthline). A separate systematic review and meta-analysis confirmed a meaningful rise in bioavailable testosterone with GLP-1 treatment (PMC). Some research even suggests part of this effect may be independent of weight loss, pointing to a possible direct action on the hypothalamic-pituitary-testicular axis (PubMed). This means it is important to keep an eye on testosterone levels for men on both GLP-1’s and Testosterone Replacement Therapy (TRT).
The picture on erectile function is similarly encouraging on balance: several meta-analyses report improved IIEF (erectile function) scores in men using GLP-1s, particularly those with obesity or type 2 diabetes (Wiley/Andrology, academic.oup.com). That said, the evidence isn't unanimous — a large FDA adverse-event analysis found a weak but statistically detectable signal for orgasmic dysfunction, erectile dysfunction, and reduced libido in a subset of men (PubMed), and one cohort study of men with type 2 diabetes found a modestly higher rate of erectile dysfunction among GLP-1 users compared with a different diabetes drug class (PMC). The most likely explanation is that individual response varies with baseline hormone status, rate of weight loss, and underlying metabolic health, rather than a uniform drug effect.
Emerging neurological and behavioral benefits. A large 2025 study using U.S. veterans' health records found GLP-1 users had reduced risk of substance use disorders, seizures, neurocognitive disorders including dementia, and several respiratory and infectious conditions (Nature Medicine, Washington University School of Medicine). The magnitude of most of these benefits was modest — roughly 10–20% relative risk reduction — but the breadth of the effect surprised researchers. We will have to monitor other potential health benefits in the future. This is a very exciting result, especially in the field of addiction medicine, if they are found to be truly beneficial for substance use disorders.
Alcohol Use Disorder. Use of GLP-1’s seems to help with the reduction in craving and alcohol consumption showing that they may influence behaviour through pathways not seemingly related to their metabolic changes or weight loss or glycemic control. This is a very interesting situation that requires further study to better understand.
The Drawbacks: What to Weigh Before Starting
Gastrointestinal side effects are common and expected. Nausea, vomiting, diarrhea, and constipation affect a large share of users, especially during dose increases, and are the leading reason people discontinue treatment (Stanford Medicine, Cleveland Clinic).
Muscle and bone loss deserve real attention for men who train. Roughly a quarter to nearly half of total weight lost on GLP-1 medications can come from lean mass rather than fat, depending on the specific drug and study (Medscape, Drugs.com). Doctors are quick to note this isn't unique to GLP-1s — any significant weight loss carries some muscle loss risk — but the scale of weight loss these drugs achieve makes resistance training and adequate protein intake especially important (Cleveland Clinic, Men's Health). Reduced bone mineral density has also been observed in some trials, which raises long-term fracture-risk questions that are still being studied (Mayo Clinic Community Health, Medscape).
Gallbladder disease and pancreatitis, while rare, are real risks. A JAMA-published analysis found GLP-1 users had a roughly nine-fold higher rate of pancreatitis compared with an older weight-loss drug, along with higher rates of intestinal obstruction and gastroparesis — though absolute risk remained under 1% per year (Medscape). UK drug regulators have also flagged gallstone disease and severe dehydration from GI side effects as risks worth monitoring (UK Government/MHRA).
Cost and the "forever drug" problem. Out-of-pocket costs commonly run $800–$1,200 per month in markets without full insurance coverage, and most people who stop taking GLP-1s regain a significant portion of the weight they lost, which raises hard questions about long-term affordability and commitment (Mayo Clinic Community Health). This has now changed with generic versions of the drugs hitting the Canadian market and with price drops across the board.
Unresolved long-term unknowns. GLP-1s for chronic weight management are still a relatively young field of use. Regulators continue to monitor for thyroid C-cell tumors (a boxed warning based on animal studies), rare eye conditions like NAION, and other effects that may only surface with widespread, multi-decade use (GoodRx, Mayo Clinic Community Health).
The Bottom Line for Men
For men carrying excess weight, especially with related conditions like type 2 diabetes, high blood pressure, fatty liver disease, or sleep apnea, and low testosterone GLP-1 medications can offer significant benefits that go well beyond the number on the scale — including a plausible boost to testosterone and cardiovascular protection that older weight-loss approaches rarely delivered this reliably (news.llu.edu). But they aren't a free lunch: GI side effects are near-universal at first, muscle and bone loss require an active countermeasure through resistance training and nutrition, rare but serious complications exist, and the financial and long-term commitment can be substantial.
As with testosterone therapy or any other significant hormonal or metabolic intervention, the right move is an honest conversation with a physician who knows your full health picture — bloodwork, past medical history, family history, and your health goals discussed — before starting.
This article is for general educational purposes and is not medical advice. Talk to your doctor before starting or stopping any medication.
References
1. Nauck, M. et al. "The expanding benefits of GLP-1 medicines." PMC, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12281309/
2. "Study Identifies Benefits and Risks of GLP-1 Drugs Across Multiple Conditions." JAMA Network, 2025. https://jamanetwork.com/journals/jama/fullarticle/2830756
3. "The expanding role of GLP-1 receptor agonists." PMC, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12303005/
4. "Recent Advances and Therapeutic Benefits of Glucagon-Like Peptide-1 Receptor Agonists." PMC, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11579408/
5. "Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists." PMC / StatPearls, NCBI, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11444311/; https://www.ncbi.nlm.nih.gov/books/NBK551568/
6. "Beyond weight loss: How GLP-1 medications are changing men's health." Loma Linda University Health News, 2026.https://news.llu.edu/health-wellness/beyond-weight-loss-how-glp-1-medications-are-changing-mens-health
7. "What Men Need to Know Now About Weight Loss Drugs." Men's Health, 2026. https://www.menshealth.com/health/a70715853/mens-health-guide-to-weight-loss-drugs/
8. "GLP-1 for Men: What's Different About Male Weight Loss." TrimRX, 2026. https://trimrx.com/blog/glp1-for-men/
9. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nature Medicine, 2025. https://www.nature.com/articles/s41591-024-03412-w
10. "Study identifies benefits, risks linked to popular weight-loss drugs." Washington University School of Medicine, 2025. https://medicine.washu.edu/news/study-identifies-benefits-risks-linked-to-popular-weight-loss-drugs/
11. "GLP-1 Drugs May Boost Testosterone Levels In Men With Obesity." Healthline, 2025. https://www.healthline.com/health-news/glp-1-drugs-may-improve-low-testosterone
12. "Effect of GLP-1 agonists on testosterone levels: a systematic review and meta-analysis." PMC, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12752444/
13. "Emerging Effects of Glucagon-Like Peptide-1 Receptor Agonists on male sexual function." PubMed, 2026. https://pubmed.ncbi.nlm.nih.gov/42011503/
14. "Effects of glucagon-like peptide 1 receptor agonists on testicular function and erectile function." Andrology (Wiley). https://onlinelibrary.wiley.com/doi/full/10.1111/andr.70022
15. "Can Glucagon-Like Peptide-1 Receptor Agonists Be used to treat erectile dysfunction?" Journal of Sexual Medicine (Oxford Academic), 2026. https://academic.oup.com/jsm/article/23/Supplement_4/qdag118.035/8701835
16. "Male sexual dysfunction associated with GLP-1 receptor agonists." PubMed. https://pubmed.ncbi.nlm.nih.gov/40240532/
17. "GLP-1 receptor agonist and risk of erectile dysfunction in men with type 2 diabetes." PMC, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC13084313/
18. "The science of safety: adverse effects of GLP-1 receptor agonists." PMC, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC12904723/
19. "GLP-1s 101: What the science says about weight loss, side effects, safety." Stanford Medicine, 2026. https://med.stanford.edu/news/insights/2026/06/glp1s-101-weight-loss-wegovy-ozempic-zepbound-side-effects-safe-use.html
20. "GLP-1 Agonists." Cleveland Clinic. https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists
21. "Increasing GLP-1 Use Raises Muscle Loss Concerns." Medscape, 2026. https://www.medscape.com/viewarticle/increasing-glp-1-use-raises-muscle-loss-concerns-2026a1000p4h
22. "Does Ozempic cause muscle loss and how to prevent it?" Drugs.com, 2026. https://www.drugs.com/medical-answers/ozempic-cause-muscle-loss-how-you-prevent-3578660/
23. "Can Ozempic Cause You To Lose Muscle?" Cleveland Clinic, 2025. https://health.clevelandclinic.org/ozempic-muscle-loss
24. "Does Ozempic Cause Muscle Loss? Doctors Explain." Men's Health, 2024. https://www.menshealth.com/health/a60338236/ozempic-muscle-loss/
25. "Pros and cons of GLP-1 agonists for weight loss." Mayo Clinic Community Health, 2025. https://communityhealth.mayoclinic.org/featured-stories/weight-loss-drugs
26. "What Is the Dark Side of GLP-1 Receptor Agonists?" Medscape, 2023. https://www.medscape.com/viewarticle/998986
27. "GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse." UK Government (MHRA), 2024. https://www.gov.uk/drug-safety-update/glp-1-receptor-agonists-reminder-of-the-potential-side-effects-and-to-be-aware-of-the-potential-for-misuse
28. "11 GLP-1 Side Effects You Should Know About." GoodRx. https://www.goodrx.com/classes/glp-1-agonists/glp-1-side-effects
29. "Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists." PubMed, 2025. https://pubmed.ncbi.nlm.nih.gov/40892610/
